Prices are updated after-hours


Sort by: gain open | gain high | gain close | publishing date

has symbol : Yes    published : Today    symbols : Lly    save search

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
Published: 2022-01-22 (Crawled : 00:20) - prnewswire.com
INCY | News | $74.95 | twitter stocktwits trandingview |
Health Technology

LLY | News | $247.43 | twitter stocktwits trandingview |
Health Technology

tyvyt cel asco injection results
Your saved searches


Save your searches and get alerts when important news are released.

Mentioned Today
COTY | News | $8.79 | twitter stocktwits trandingview |
Consumer Non-Durables

DXR | News | $11.075 | twitter stocktwits trandingview |
Health Technology

FCFS | News | $70.6 | twitter stocktwits trandingview |
Finance

INCY | News | $74.95 | twitter stocktwits trandingview |
Health Technology

KRP | News | $14.56 | twitter stocktwits trandingview |
Miscellaneous

LLY | News | $247.43 | twitter stocktwits trandingview |
Health Technology

OVLY | News | $17.5101 | twitter stocktwits trandingview |
Finance